An Early Phase 1 interventional study of Short chain fructo-oligosaccharide (scFOS) 5 g and Placebo in Healthy, sponsored by University of Minnesota. Completed at 1 site in United States. Open to participants aged 18 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2010-04-09.
Sponsored by University of Minnesota · Early Phase 1, Interventional, and Prevention
Populations that report high fiber consumption demonstrate lower rates of obesity. Enhanced satiety may play a key role in this relationship. The colonic fermentation of fibers is theorized to influence satiety and food intake. Short chain fructooligosaccharide (scFOS) are rapidly fermentable fibers that can easily be added to foods to impact these parameters.
The objective of this study was to evaluate the satiety response of scFOS and its ability to decrease food intake.
Intervention study with fiber added to beverages and acute effects on satiety measured.
University of Minnesota is the lead sponsor of 1,210 studies on the registry; 194 are open to participants now.
Of its 133 completed or terminated interventional studies of FDA-regulated products, 92 (69%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
No treatment
Other: Placebo
5 g scFOS
Dietary Supplement: Short chain fructo-oligosaccharide (scFOS) 5 g
8 g scFOS
Dietary Supplement: Short chain fructooligosaccharide (scFOS) 8 g
Dietary Supplement: scFOS 5 g Novel fiber administered in two 5 g doses--the first in a beverage and the second in a solid chew.
Also known as: fructo-oligosaccharide
Treatment without scFOS fiber
Novel fiber administered in two 8 g doses--the first in a beverage and the second in a solid chew.
Satiety response using visual analogue scales
Satiety response was measured using subjective perceptions of hunger, fullness, satisfaction, and prospective food intake evaluated by previously validated visual analogue scales (VAS).
Time frame: 0, 15, 30, 45, 60, 90, 120, 180, 240 minutes postprandially
Ad libitum food intake
Time frame: 240 minutes postprandially and over 24 hours
Breath hydrogen response
Time frame: 0, 240 minutes
Gastrointestinal tolerance using visual analogue scales (VAS)
Subjective ratings of bloating, stool consistency, and flatulence on VAS. A stool count was also recorded.
Time frame: 24 hours
This study is completed, as verified in Apr 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.